Online inquiry

IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13276MR)

This product GTTS-WQ13276MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13276MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12986MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ5813MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ4581MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13414MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ11622MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ14243MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ8790MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ15938MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW